Earlier Anakinra Initiation Warranted in Still's Disease Save
An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK).
A total of 141 AOSD patients were retrospectively studied.
Overall, they found no differences in efficacy if ANK was started within 6 (or 12 mos) vs. thereafter.
However, starting ANK earlier (
ANK effectiveness in controlling systemic inflammation and resolving articular manifestations is more obvious when IL-1 inhibition is initiated soon after disease onset.